Accès membres
Mot de passe perdu - Devenir membre
Espace Patients
..............................................................
Pathologies
..............................................................
Annuaire des membres
..............................................................
Devenir membre
..............................................................
En direct de...
..............................................................
En direct de...
 

ENDO 2017


SFE 2016


ECE 2016


ENDO 2016


Annuaire Laboratoire Recherche


signalisation, métabolisme et progression tumorale

Coordonnées :
Gérald Raverot
Centre de Recherche en Cancérologie de Lyon
Cheney D - 4ème étage
Centre Léon Bérard
69372 LYON CEDEX 08
Tél : +33 (0)4 69 16 66 69 Philippe BERTOLINO
Tél : +33 (0)4 72 11 93 25 Pr Gérald RAVEROT
Téléphone : +33 (0)4 72 11 93 25
http://www.crcl.fr/667-Activin-Signaling-in-Tumor-group.crcl.aspx?language=fr-FR
gerald.raverot@chu-lyon.fr

Affiliation : INSERM U1052, CNRS UMR5286,
Directeur : Pr Germain Gillet
Responsables Equipe hypophyse:
Professeur Gérald RAVEROT
Philippe Bertolino
Thème générale de recherche : Tumeurs Hypophysaires
Thème de recherche lié à l'endocrinologie : Tumeurs Hypophysaires
CGH, trasncriptome, marqueur pronostique, carcinome hypophysaire, tumeur hypophysaire

Actualités du labo :
* Chanal M, Chevallier P, Raverot V, Fonteneau G, Lucia K, Monteserin Garcia JL,Rachwan A, Jouanneau E, Trouillas J, Honnorat J, Auger C, Theodoropoulou M, Raverot G. Differential effects of PI3K and dual PI3K/mTOR inhibition in rat prolactin-secreting pituitary tumors. Mol Cancer Ther. 2016 Mar 16. pii: molcanther.0891.2015. [Epub ahead of print] PubMed PMID: 26983879.

* Patry M, Teinturier R, Goehrig D, Zetu C, Ripoche D, Kim IS, Bertolino P, Hennino A. ?ig-h3 Represses T-Cell Activation in Type 1 Diabetes. Diabetes. 2015 Dec;64(12):4212-9. doi: 10.2337/db15-0638. Epub 2015 Oct 15. PubMed PMID:26470788

* Bonnavion R, Teinturier R, Jaafar R, Ripoche D, Leteurtre E, Chen YJ, Rehfeld JF, Lepinasse F, Hervieu V, Pattou F, Vantyghem MC, Scoazec JY, Bertolino P, Zhang CX. Islet Cells Serve as Cells of Origin of Pancreatic Gastrin-PositiveEndocrine Tumors. Mol Cell Biol. 2015 Oct;35(19):3274-83. doi:10.1128/MCB.00302-15. Epub 2015 Jul 13. PubMed PMID: 26169832;

* Ripoche D, Charbord J, Hennino A, Teinturier R, Bonnavion R, Jaafar R, Goehrig D, Cordier-Bussat M, Ritvos O, Zhang CX, Andersson O, Bertolino P. ActivinB Is Induced in Insulinoma To Promote Tumor Plasticity through a ?-Cell-Induced Dedifferentiation. Mol Cell Biol. 2015 Dec 28;36(5):756-64. doi:10.1128/MCB.00930-15. PubMed PMID: 26711255; PubMed Central PMCID: PMC4760219.

* Delgrange E, Vasiljevic A, Wierinckx A, François P, Jouanneau E, Raverot G, Trouillas J. Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol. 2015 Jun;172(6):791-801. doi: 10.1530/EJE-14-0990. Epub 2015 Mar 19. PubMed PMID: 25792376.

* Esposito F, De Martino M, D'Angelo D, Mussnich P, Raverot G, Jaffrain-Rea ML, Fraggetta F, Trouillas J, Fusco A. HMGA1-pseudogene expression is induced in human pituitary tumors. Cell Cycle. 2015;14(9):1471-5. doi: 10.1080/15384101.2015.1021520. PubMed PMID: 25894544; PubMed Central PMCID: PMC4615119.

* Chinezu L, Vasiljevic A, Jouanneau E, François P, Borda A, Trouillas J, Raverot G. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using Immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol. 2014 Jan;45(1):71-7. doi:10.1016/j.humpath.2013.08.007. Epub 2013 Oct 31. PubMed PMID: 24182563.

* Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E,François P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA,Figarella-Branger D, Raverot G; members of HYPOPRONOS, Barlier A, Bernier M,Bonnet F, Borson-Chazot F, Brassier G, Caulet-Maugendre S, Chabre O, Chanson P,
Cottier JF, Delemer B, Delgrange E, Di Tommaso L, Eimer S, Gaillard S, Jan M,Girard JJ, Lapras V, Loiseau H, Passagia JG, Patey M, Penfornis A, Poirier JY,Perrin G, Tabarin A. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013 Jul;126(1):123-35. doi:10.1007/s00401-013-1084-y. Epub 2013 Feb 12. PubMed PMID: 23400299.

* D'Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G, Fedele M,Maria Croce C, Trouillas J, Fusco A. Altered MicroRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab. 2012 May 7. [Epub ahead of print] PubMed PMID: 22564666.

* Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T. Pituitary carcinomas and aggressive pituitary tumours:merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf). 2012Jun;76(6):769-75.

* Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J,Trouillas J, Raverot G. New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary. 2012 Mar;15(1):37-43.

* Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C,Jouanneau E, Chanson P, Trouillas J, Lachuer J. Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol. 2011 Sep;21(5):533-43.

* Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P,Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010 Oct;95(10):4592-9. Epub 2010 Jul 21. PubMed PMID: 20660056.

* Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J,Pugeat M, Trouillas J. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol. 2010 Jul;163(1):35-43. Epub 2010 Apr 12.

* Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J, Trouillas J. Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol. 2010 Sep 15;326(1-2):30-9. Epub 2010 Mar 6.

* Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J;HYPOPRONOS. Prognostic factors in prolactin pituitary tumors: clinical,histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab. 2010 Apr;95(4):1708-16.

<< Retour

Ce site respecte les principes de la charte HONcode de HONCe site respecte les principes de la charte HONcode.

Vérifiez ici.
SFendocrino.org

© 2010 - 2017 l Société Française d'Endocrinologie l Secrétariat permanent : Centre d'Affaires Regus - Paris Gare de Lyon 37-39, avenue Ledru-Rollin - 75012 Paris
Tél. : 33 (0)1 40 24 02 72 l Fax : 33 (0)1 40 24 02 71 l Siège social : 88, rue de la Roquette - 75011 PARIS l Mentions légales l Contact